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Analysis
Web-based intervention for depressive symptoms
in adults with types 1 and 2 diabetes mellitus: a
health economic evaluation
Stephanie Nobis, David Daniel Ebert, Dirk Lehr, Filip Smit, Claudia Buntrock, Matthias Berking,
Harald Baumeister, Frank Snoek, Burkhardt Funk and Heleen Riper
Background
Web-based interventions are effective in reducing depression.
However, the evidence for the cost-effectiveness of these
interventions is scarce.
Aims
The aim is to assess the cost-effectiveness of a web-based
intervention (GET.ON M.E.D.) for individuals with diabetes and
comorbid depression compared with an active control group
receiving web-based psychoeducation.
Method
We conducted a cost-effectiveness analysis with treatment
response as the outcome and a cost-utility analysis with quality-
adjusted life-years (QALYs) alongside a randomised controlled
trial with 260 participants.
Results
At a willingness-to-pay ceiling of €5000 for a treatment response,
the intervention has a 97% probability of being regarded as cost-
effective compared with the active control group. If society is
willing to pay €14 000 for an additional QALY, the intervention has
a 51% probability of being cost-effective.
Conclusions
This web-based intervention for individuals with diabetes and
comorbid depression demonstrated a high probability of being
cost-effective compared with an active control group.
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Diabetes and depression are highly prevalent conditions and often
co-occur. Compared with the general population, individuals diag-
nosed with diabetes have a higher risk of developing depressive
symptoms (odds ratio = 1.38).1 Both conditions are associated
with a considerable disease burden2,3 and substantial healthcare
costs.4,5 In a systematic literature review, eight cost-of-illness
studies showed a significant difference between the healthcare
costs of individuals with diabetes and comorbid depression and
those with diabetes without depression.6 Comorbid depression
increased the diabetes-related costs by between 35 and 300%.6
Another study in the USA showed that diabetes and comorbid
depression led to increased presenteeism and absenteeism.
Individuals with comorbid minor depression had a 1.7-fold
increased risk and those with comorbid major depression had a
2.8-fold increased risk of missing more than 5 workdays in the
past month compared with individuals who only had diabetes.7
Interventions to reduce depression in diabetes mellitus
A Cochrane review on individuals with diabetes and comorbid
depression showed that psychological and pharmacological inter-
ventions can be an effective approach to reduce depressive
symptoms.8 The effect of these interventions on diabetes-related
outcomes, such as glycaemic control and diabetes management,
are mixed.8,9 Evidence concerning the cost-effectiveness of depres-
sion treatment in individuals with diabetes mellitus is marginal.10
Web-based interventions are a promising additional treatment
option for individuals with depression. A meta-analysis shows that
they are successful in reducing symptoms of depression,11 even in indi-
viduals with diabetes.12–14Web-based interventions are often assumed
to offer several advantages, such as reaching individuals who were
untreated for many years12 and being cost-effective compared with
face-to-face therapies.15 However, there have been few trials that
have evaluated the cost-effectiveness of web-based interventions for
depression, and their results showed that they do have the potential
to be cost-effective.16–20 To the best of our knowledge, no study has
examined the cost-effectiveness of a web-based intervention for the
subpopulation of individuals with diabetes and comorbid depression.
In previous analyses, we demonstrated that the web-based inter-
vention GET.ON Mood Enhancer Diabetes (GET.ON M.E.D.) was
effective in reducing symptoms of depression over 2 and 6 months
among individuals with types 1 and 2 diabetes mellitus and
comorbid depression.12,13 This study evaluates, from a societal per-
spective, the cost-effectiveness and cost utility of this web-based
intervention for symptoms of depression in people with diabetes
compared with an active control group receiving psychoeducation.
Method
Design and participants
The study’s design was described in detail elsewhere.21 In brief, this
study was designed as a health economic evaluation alongside a ran-
domised controlled trial that was conducted with two parallel
groups that were measured at baseline and at 2 and 6 months
post-baseline. The aim was to include costs and savings associated
with improvement in depression. We did not include costs and
savings due to changes in diabetes control. In total, 260 individuals
with diabetes and symptoms of comorbid depression were ran-
domly allocated to either the intervention or to an unguided web-
based psychoeducation session for depression. Block randomisation
was performed using an automated, web-based program (random-
isation.eu) and a 1:1 ratio. Participants were included in the study if
they were 18 years or older, had been diagnosed with type 1 or type 2
diabetes mellitus for a minimum of 3months and had clinically rele-
vant depressive symptoms, as measured with a Center for
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Epidemiological Studies Depression Scale (CES-D) score ≥23.22,23
The exclusion criteria were risk of suicide, currently receiving psy-
chotherapy or being on a waiting list for such treatment. The study
was approved by the Ethics Committee of the Philipps University of
Marburg, Germany. The trial was registered in the Deutsches
Register Klinischer Studien, the German clinical trial registry,
under registration number DRKS00004748.
Interventions
The GET.ONM.E.D. intervention consisted of sixminimally guided
online sessions, two optional sessions (addressing overweight and
healthy sleep) and an optional booster session after 4 weeks. The
primary aim of this intervention was to reduce symptoms of depres-
sion. The intervention was based on cognitive–behavioural therapy
(CBT) (systematic behavioural activation24 and problem solving25)
and included homework assignments and an online mood diary.
Each session contained diabetes-specific themes. Participants were
supported by a coach who provided personalised written feedback
(approximately 350 words) within 48 h after receiving the home-
work. The communication between the participants and the
coaches took place in an asynchronous way via the internal messa-
ging function on the GET.ON M.E.D. platform. Each coach was
supervised by an experienced clinical psychologist. The individuals
in the control group received a self-help, web-based, psychoeduca-
tion session26 on the same platform. It informed participants about
the nature of and evidence-based treatments for depression. The
session focused only on symptoms of depression, not diabetes-
related issues. All participants had full access to treatment as
usual (e.g. psychotherapist and general practitioner).
Outcome measures
The clinical outcome for the cost-effectiveness analysis was the
number of participants who were classified as having a favourable
treatment response in terms of depressive symptom severity,
according to the CES-D22 and the Reliable Change Index (RCI)27
after 6 months (see Statistical analysis). The internal consistency
of the CES-D is high (Cronbach’s α = 0.87–0.92 in various
German samples),22 and this study had a Cronbach’s α of 0.91.
Quality-adjusted life-years (QALYs)28 were used as the primary
outcome of the cost-utility analysis. To compute QALYs, we used
the EQ-5D-3L29 and the well-validated British standardised value
set.30 Responders completed the EQ-5D-3L at baseline and after
2 and 6 months. This questionnaire consists of five items including
mobility, self-care, usual activities, pain/discomfort and anxiety/
depression, each of which is rated as causing ‘no problems,’ ‘some
problems’ or ‘extreme problems’.29
Measuring resource use
At baseline and 6 months after randomisation, we assessed the
direct and indirect costs that were incurred 3 months before the
assessments. The economic evaluation was performed from a soci-
etal perspective, which includes direct medical costs, direct non-
medical costs and indirect costs. The costs were calculated in
Euros (€) for the reference year 2013. We used the ‘Trimbos
Institute and Institute of Medical Technology Questionnaire for
Costs Associated with Psychiatric Illness’ (Tic-P)31 cost question-
naire, adapted for the German healthcare system. The participants
were instructed to report all of their healthcare use and productivity
losses. We followed the guidelines from Krauth and colleagues32
and from Bock and colleagues33 regarding the use and calculation
of standardised unit costs in the German healthcare system. To
assess the presenteeism and absenteeism costs, we adhered to the
recommendations from the Dutch Tic-P manual.31 Moreover, we
followed the recommendations of the Consolidated Health
Economic Evaluation Reporting Standard.34
Intervention costs
Themanufacturer of GET.ONM.E.D. estimated the average price of
the intervention to be €150 per participant. The costs for developing
and hosting the intervention are included in this flat tariff. We
added €10 for each feedback session as this was the actual
payment received by the coaches. Moreover, at the end of each
lesson participants were asked how much time they had spent on
the intervention. On average they needed 30 min for each session.
Based on Krauth and colleagues,32 the opportunity costs per hour
were calculated at €23.10. Therefore, we estimated intervention
costs of €283.46 (€63.18 feedback costs + €150 intervention costs
+ €70.28 opportunity costs).
For the control group, which received web-based psychoeduca-
tion, we calculated €23.10 (1 h opportunity costs) for reading the
information and €10 for the manufacturers’ time and effort in pre-
paring an online psychoeducational session. It was assumed that all
of the participants owned a computer and had internet access, so
these costs were not included.
Direct medical costs
Direct medical costs included costs for any type of healthcare ser-
vices (e.g. treatment time by health experts, time for homework
assignments and health activities) and for medications. The costs
of visits to a medical doctor or other healthcare services were
based on the results and recommendations of Bock and colleagues33
and were indexed for 2013. The costs of medications, such as anti-
depressants, were based on the German drug register (Rote Liste).
Here, we followed the recommendations from Bock33 and
Krauth32 and calculated the arithmetic mean of the costs of the
three largest packaging forms of the same agent, minus the pharma-
cist clawback, weighted by the statutory population share (89%).
The only costs we did not measure were the direct medical costs
of diabetes drugs (e.g. insulin), as these costs for type 1 and type 2
are very different.
Direct non-medical costs
Direct non-medical costs included costs for making the return trip
to a healthcare service, for example, a general practitioner. A receipt
for the cost of travelling by bus or taxi was requested; each kilometre
was valued at €0.30. If no receipt was provided, the cost was calcu-
lated based on the average costs according to the German mileage
lump-sum charge.
Costs of productivity losses
Indirect costs refer to productivity losses due to absenteeism and
presenteeism in paid work and due to impairments in the ability to
perform domestic tasks, expressed as the number of hours that
others must spend performing those chores. Productivity costs
were based on the human capital approach;28 specifically, the partici-
pants are asked whether they had been absent from work during the
past 3 months (absenteeism). These days were multiplied by their
average gross daily wage. Productivity losses may also occur when
people feel ill while at work, which may result in lesser efficiency
(presenteeism). Therefore, the participants were asked to report the
number of days that they felt ill but continued to work. These days
were multiplied by a self-reported inefficiency score, which ranged
between 0 and 1 (1 represents totally inefficient, and 0 represents
as efficient as when in good health), to obtain workday equivalents
lost to presenteeism. Subsequently, their gross wages per hour were
calculated based on their self-reported monthly salary and were
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used to calculate the costs of presenteeism.31 Finally, people may not
be able to perform domestic tasks and may thus, for example, receive
help from their family members. These costs were valued as the price
of domestic help at €18.33 per hour (which is essentially a shadow
price for these costs).33
Statistical analysis
This study was powered to detect a mean difference of d = 0.35 in the
primary outcome (CES-D) between the groups at post-measurement.
This study was not powered to statistically test the differences in
health economic outcomes. Therefore, we adopt a probabilistic deci-
sion-making approach for making health economic inferences.35
Analyses of clinical outcomes
All analyses were conducted in accordance with the intention-to-
treat (ITT) principle. All of the participants completed the baseline
assessment. Consistent with previous evaluations of this study,12,13
the missing data at follow-up were imputed using a Markov chain
Monte Carlo multivariate imputation algorithm (missing data
module in SPSS version 20) with ten estimations per missing
value, and we then aggregated the ten estimations.36
We included concurrent use of antidepressants, age, duration of
diabetes, family status and use of other psychological treatments
during the trial period as covariates in the primary outcome ana-
lysis. As none of these variables were a predictor of the outcome,
we excluded them from the final model.
We categorised the participants as responders according to the
widely used RCI.27 The participants with a reliable positive change
(greater than −8.99 points on the CES-D) were classified as ‘reliably
improved’. Next, we determined the number of participants who
had scores below 23 on the CES-D22 in both groups and who
were also categorised as being reliably improved.27 We assumed
that the participants who fulfilled both of these criteria achieved a
clinically relevant improvement; accordingly, we labelled them as
participants with a ‘treatment response’. The utility scores obtained
with the British tariffs for the EQ-5D were used to calculate the
QALYs gained or lost during the 6-month study period. QALYs
gained per individual in each group during the trial period were cal-
culated using linear interpolation between measurement points
(baseline, 2 months, and 6 months) and then accumulating these
points over time using the area under the curve (AUC) method.37
Analysis of costs
The costs were determined at baseline and at the 6-month follow-
up. Missing data were completed using the regression imputation
methods in Stata version 13.0. Because group allocation was a sig-
nificant predictor of missing cost data, it was used as predictor in
this model. The cumulative costs for each participant during the
6-month follow-up period were estimated by calculating the AUC
of linearly interpolated 1-month costs, adding the respective inter-
vention costs to both groups.
Analysis of cost-effectiveness and cost utility
For the cost-effectiveness and cost-utility analyses, the costs and
effects were calculated for a 6-month period. In both analyses, the
incremental cost-effectiveness ratio (ICER) was calculated using
the following formula:
ICER ¼ cost IG cost CG
effect IG effect CG ;
where IG refers to the intervention group and CG refers to the
control group.
The incremental cost-utility ratio (ICUR) was computed in the
same manner. The non-parametric bootstrap resampling techni-
ques (with 2500 replications) were used to consider the uncertain-
ties surrounding the ICER and the ICUR. The bootstrap analyses
were performed using Microsoft Office Excel 2010. The results are
presented in a cost-effectiveness plane. The intervention is accept-
able if lower costs are associated with more treatment responses
(south-east quadrant). In this case, the intervention ‘dominates’
the active control group. If the ICER/ICUR falls in the north-east
quadrant, the intervention is estimated to generate superior health
outcomes at greater costs. In the north-west quadrant, the interven-
tion is estimated to be inferior, with higher costs and losses in health
compared with the control group (worst possible outcome of the
intervention); the intervention is then unacceptable from a cost-
effectiveness perspective. If the ICER/ICUR falls in the south-west
quadrant, the intervention is estimated to produce inferior health
outcomes compared with the control, but at lower costs.
When the bulk of simulated ICERs fall in the north-east quad-
rant, we must determine whether the extra health gains are worth
the extra costs. To answer that question, an incremental cost-effect-
iveness acceptability curve was estimated.38 This curve shows the
probability that the intervention is cost-effective compared with
the psychoeducation control group over a range of willingness-to-
pay (WTP) ceilings to pay for one treatment response or for one
QALY gained. This approach reflects the idea that people are gen-
erally willing to pay for health improvements, although there is
no consensus on the WTP threshold for one QALY gained.39
Sensitivity analyses
Three sensitivity analyses of intervention costs were conducted to
test the robustness of the findings. In the primary analysis, we esti-
mated intervention costs to be €283.46. Given the fact that web-
based interventions are not implemented into routine care in
Germany, there is uncertainty concerning these costs. We therefore
repeated all of the analyses assuming different intervention costs; i.e.
by reducing the costs by 50% (€141.73), increasing costs by 50%
(€426.19) and increasing costs by 100% (€566.92).
Results
Sample
Over half of the participants (n = 142, 55%) had physician-diag-
nosed type 2 diabetes. A lot of the participants reported a long dia-
betes duration, e.g. 46% (n = 119) had been living with type 1 or type
2 diabetes for more than 10 years. The participants were middle
aged (mean = 51 years), well educated (45% college qualification
or higher) and predominantly female (63%). At baseline, their
mean CES-D score was 32, which indicates a highly depressed
target group.22,23 The DSM-IV (1994)40 depression diagnosis was
measured with a telephone-administered Structured Clinical
Interview for DSM-IV Axis I Disorders.41 The most common diag-
nosis was partially remitted depression (34%), followed by recurrent
major depression (30%) and current major depression (24%).
Overall, 80 (62%) out of the 129 participants from the intervention
group completed all six sessions at 2 months follow-up. Detailed
sample information is presented in a previous paper.12
Study drop outs
The ITT analysis included 256 participants because 4 participants
(IG = 1; CG = 3) requested the deletion of their data, as permitted
under the medical ethics rules in Germany. After 6 months,
182 (71%) of the 256 participants completed the web-based
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questionnaires. A higher drop-out rate was observed in the inter-




In the intervention group, 90 (70%) of the 129 individuals were clas-
sified as being reliably improved and 77 (60%) of these 90 partici-
pants also had a CES-D below 23 and, thus, reached a treatment
response at the 6-month follow-up assessment. In comparison,
23 (18%) of the 128 individuals in the control group reached a
treatment response at the 6-month follow-up. These findings
correspond to a likelihood ratio of 0.60/0.18 = 3.35 (95% CI =
2.25–4.97), indicating that the likelihood of a favourable outcome
wasmore than tripled for the intervention group. The likelihood dif-
ference between the groups was 0.60–0.18 = 0.42 (95% CI = 0.31–
0.53), and its inverse 1/0.42 indicated a number needed to treat of
2.37 (95% CI = 1.89–3.18).
QALYs
For the control group, the average utility score was 0.61 (s.d. = 0.26)
at baseline, 0.63 (s.d. = 0.27) at post-measurement (2 months) and
0.69 (s.d. = 0.19) at the 6-month follow-up. For the intervention
group, the mean utility score was 0.62 (s.d. = 0.25) at baseline,
0.66 (s.d. = 0.27) at post-measurement (2 months) and 0.69
(s.d. = 0.18) at the 6-month follow-up.
After applying the AUC method, the mean QALYs gained in
the intervention group was 0.33 (s.d. = 0.11) compared with 0.32
(s.d. = 0.11) in the control group after 6 months. No significant dif-
ferences were found between the groups (F1254 = 0.42, P = 0.51).
Costs
The average costs accumulated per participant over the 6-month
period are presented in Table 1 for direct medical, direct non-
medical and indirect costs. The results are reported for both
groups and for the differences between the groups.
The GET.ON M.E.D. intervention was calculated at €283 per
participant, whereas the added cost of psychoeducation in the
control group was €33. After 6 months, the direct costs were, on
average, higher in the intervention group compared with the
active control group. Regarding the indirect costs, the individuals
in the intervention group produced higher absenteeism costs but
fewer presenteeism costs than those in the control group.
Moreover, the domestic help costs were lower in the intervention
group. Overall, the average cost per participant in the intervention
group was €5195 compared with €5098 in the control group. The
mean costs were therefore €97 higher in the intervention group
than in the control group after 6 months.
Cost-effectiveness
In summary, (a) the intervention resulted in more participants with
a favourable treatment response compared with the psychoeduca-
tion control group (60 v. 18%), and (b) the intervention group
had a higher average cost per participant (€5195 v. €5098). The sub-
stitution yield is therefore (5195–5098)/(0.60–0.18) = 233; meaning
that for each participant that receives the GET.ONM.E.D. interven-
tion (with a treatment response) instead of the psychoeducation, an
extra cost of €233 is incurred.
In the cost-effectiveness plane (Fig. 1), the majority of the simu-
lated ICERs were located in the north-east quadrant, indicating a
54% probability that the intervention generates better clinical out-
comes compared with the control, but the intervention is also asso-
ciated with additional costs. The other ICERs fell in the south-east
quadrant, indicating a 46% probability that better health outcomes
are achieved for lower costs in the intervention group compared
with the control group.
Figure 2 shows that a 48% probability that the intervention was
cost-effective at aWTP of €0 per treatment response compared with
the control group. This probability increased to well above the 50%
probability cut-off (64%) if society is willing to pay €1000 for a treat-
ment response. The probability that the intervention was cost-
effective at a WTP of €5000 per treatment response was 97%.
Cost utility
The estimated costs for the participants in the intervention were
higher (€5195 v. €5098) and the effects on QALYs were slightly




(N = 128) Incremental costs
P-value
Mean in € (s.d.) Mean in € (s.d.) Mean in €
Direct costs
Intervention + guidance + time 283 (0) 33 (0) 250 >0.01
Medical practitionera 457 (278) 383 (256) 74 >0.05
Psychological supportb 131 (316) 147 (375) −16 0.71
Travel expenses 69 (99) 50 (56) 19 0.06
Antidepressants/drugs 120 (282) 96 (184) 24 0.42
General sales list medicine 22 (63) 18 (65) 4 0.62
Hospital in-patient 506 (1857) 366 (2122) 140 0.56
Hospital semi-residential 396 (1699) 170 (1486) 226 0.26
Rehabilitation 104 (463) 112 (752) −8 0.92
Additional servicesc 141 (241) 188 (528) −47 0.36
Opportunity costsd 886 (1371) 754 (1091) 132 0.36
Indirect costs
Absenteeisme 1752 (1371) 1353 (2221) 399 0.16
Presenteeisme 1336 (1790) 1885 (3167) −549 0.08
Domestic help 405 (745) 945 (2913) −540 >0.05
Total cost 5195 (5470) 5098 (7172) 97 0.90
a. Contacts with general practitioner, specialist in internal medicine or other.
b. Contacts with psychologist, psychotherapists or neurologists.
c. For example, physiotherapy or osteopathy.
d. Time for health activities, time taken by health experts for homework assignments and waiting times by general practitioner.
e. In concordance with the human capital approach, we included only the participants who were able to work (e.g. excluding retired persons). We included 72 participants in the control
group and 70 participants in the intervention group.
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better but not statistically significant (0.33 v. 0.32). The cost-utility
analysis showed that the ICER for the intervention v. the psychoe-
ducation control group resulted in €10 708 per QALY gained.
Hence, each QALY gained by offering GET.ON M.E.D. instead of
psychoeducation required an extra cost of €10 708.
Of the simulated ICURs, 37% fell in the north-east quadrant,
indicating a 37% probability that the intervention generates more
QALYs – but at higher costs – compared with the control. The
south-east quadrant contained 13% of the ICURs, indicating that
the intervention is both less costly andmore effective. The acceptabil-
ity curve showed a 46% likelihood that the intervention should be
regarded as more cost-effective than psychoeducation when the
WTP for gaining a QALY is nil. The probability of GET.ON M.E.
D. being more cost-effective increases to 51% when the WTP for
gaining a QALY is increased to €14 000, which is well below a conser-
vative WTP ceiling of € 20 000 per QALY gained.39
Sensitivity analyses
We conducted three sensitivity analyses (Table 2) for the costs of the
GET.ON M.E.D. intervention because there was uncertainty con-
cerning the price when implementing the intervention into
routine care. In the first scenario, in which we assumed 50%
lower costs of the intervention, each individual with a treatment
response would be associated with a cost saving of €86 compared
with the control group after 6 months. In the second and third scen-
arios, the ICERs increased to €596 and €933, i.e. the intervention
cost was estimated to be 50% and 100% more expensive,
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Fig. 2 Cost-effectiveness acceptability curve for the costs and treatment response of the participants.
Web-based intervention for depressive symptoms in adults with types 1 and 2 diabetes mellitus
203
Downloaded from https://www.cambridge.org/core. 17 Nov 2020 at 13:16:54, subject to the Cambridge Core terms of use.
respectively. However, in all of the cases, there is nearly a 100%
probability of falling below a WTP of €10 000.
Discussion
Main findings
This study evaluated the cost-effectiveness and cost utility of a min-
imally guided, web-based, self-help intervention for individuals with
types 1 and 2 diabetes mellitus aimed at reducing symptoms of
depression, compared with an active psychoeducation control
group.
After 6 months, 60% of the individuals who had received the
GET.ON M.E.D. intervention showed treatment response com-
pared with 18% of the control group. However, treatment response
was not reflected in corresponding gains of QALYs, as we found no
statistically significant difference between the conditions after
6 months. The EQ-5D is regarded as a standard measurement
instrument to measure QALYs. However, it is unclear whether
EQ-5D is sensitive enough to detect changes in quality of life for
patients with mental health problems.42,43 Moreover, another
explanation is that the impact of the intervention was not large
enough to improve the quality of life of the intervention group com-
pared with the control group.
In the cost-effectiveness and cost-utility analyses, we demon-
strated that the intervention showed a higher probability of being
regarded as cost-effective compared with the control condition
from a societal perspective. At a WTP ceiling of €5000 for a treat-
ment response, the intervention had a 97% probability of being
regarded as cost-effective. Moreover, when the WTP ceiling for
gaining a QALY was €14 000, the intervention had a 51% probabil-
ity of being the preferred option, which is slightly below a conserva-
tive WTP ceiling of €20 000 per QALY gained.
Comparison with findings from other studies
To the best of our knowledge, this study is the first to evaluate the
cost-effectiveness of a web-based, guided, self-help intervention
for individuals with diabetes and comorbid depression. Hence,
only a comparison with cost-effectiveness studies concerning
web-based interventions for depression in general is possible.
We identified five other studies evaluating the cost-effectiveness
of a web-based depression intervention.16–20 For example,
Warmerdam and colleagues17 conducted a cost-utility and cost-
effectiveness study of internet-based treatments for adults with
depression at a 3-month follow-up. In the cost-effectiveness ana-
lyses, offering CBT resulted in additional costs of €1817 for each
additional participant, with a clinically significant change in the
severity of symptoms of depression. At aWTP of zero for a clinically
significant change in depressive symptoms, the probability that CBT
was more cost-effective than the waiting list was approximately
30%. They found that the cost of gaining one QALY by participating
in web-based CBT (iCBT) was €22 609 compared with a waiting list
control. Without anyWTP for gaining a QALY, the probability that
iCBT was more cost-effective than the waiting list group was 28%.17
The economic evaluations from Hollinghurst,16 Gerhards18 and
McCrone19 also concluded that iCBT had a high probability of
being cost-effective. Recently, Geraedts and colleagues20 conducted
an economic evaluation of a web-based guided depression interven-
tion for employees compared with care as usual after 12 months.
With a WTP of zero, the intervention’s probabilities of cost-effect-
iveness was 65% from a societal perspective and 55% from an
employer’s perspective However, they concluded that the interven-
tion was not a cost saving from an employer’s perspective.20
The results of this study underline the potential of web-based
interventions as an additional, cost-effective treatment opportunity
in reducing symptoms of depression. However, the evidence for the
cost-effectiveness of web-based depression interventions is limited
and has little bearing on our study because the differences in health-
care systems and study participants may confound outcomes.
Limitations
The first limitation of this study is the attrition rate at the 6-month
follow-up, which was substantial at 29%. We used ITT analyses and
imputation techniques to handle missing data for both effects and
costs.36,44 However, we cannot exclude a potential bias due to
missing data. Second, this study was not powered to statistically
test the health economic differences. Rather, we relied on non-para-
metric and medical decision-making techniques to make infer-
ences.35 Third, the costs and effects were evaluated over
6 months. It is, therefore, not possible to draw conclusions about
the longer-term follow-up or the dynamic development of costs.
Fourth, we only focused on the societal perspective; other perspec-
tives, such as that of the healthcare payer, are also important. Fifth,
we did not include costs for diabetes drugs; these costs can have a
huge impact on diabetes-related costs and further studies should
focus on this. Our findings should thus be interpreted with caution.
Conclusion
To summarise, the GET.ONM.E.D. intervention has been shown to
have a high probability of being cost-effective in treating comorbid
symptoms of depression in individuals with type 1 or type 2 diabetes
Table 2 Incremental cost-effectiveness ratio for the control group compared with three adjusted versions of costs for the GET.ON M.E.D. intervention
Control group Unadjusted Adjusted costs
−50% +50% +100%
Cost (€) 5098 5195 5054 5338 5479
Effect 0.18 0.60 0.60 0.60 0.60
ICER: median (€) 233 −86 596 933
Distribution on the cost-effectiveness plane:
First quadrant (north east) 54 49 61 66
Second quadrant (inferior: north west) 0 0 0 0
Third quadrant (south west) 0 0 0 0
Fourth quadrant (dominant: south east) 46 51 39 34
Willingness to pay ceiling (%)
€0 48 53 42 37
€3000 87 90 73 67
€5000 97 97 92 90
€10 000 99 99 99 99
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mellitus compared with an active psychoeducation control group,
especially from a cost-effectiveness perspective. Given the increas-
ing number of individuals with diabetes and symptoms of depres-
sion, and the fact that only a small number of these people are
reached by currently available healthcare services,45 further research
is necessary to compare such web-based interventions with routine
treatment so that policy recommendations can be made.
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psychiatry in literature
The psychology of enhanced memory in Mark Twain’s Life
on the Mississippi
Alistair Stewart
The 2006 finding of increased grey matter volume in the posterior hippocampus in London taxi
drivers who have had to learn ‘The Knowledge’ is well known. Mark Twain addressed a similar
subject phenomenologically in his 1883 book Life on the Mississippi.
Samuel Clemens took his pen name from the cry on a paddle steamer meaning ‘Safe water! Go
ahead!’ He earned his right to it from the 5 years he spent in his 20s as a pilot on the Mississippi
steamboats. These pilots faced a considerable challenge: ‘Ol’ Man River’ was a vast and unpre-
dictable waterway whose muddy banks were constantly shifting, creating and then swallowing
islands reefs and sandbanks, generating new currents, eddies, channels and treacherous shallows.
To his dismay, Twain was told by his mentor Mr Bixby that he would have to ‘learn the shape of the
river in all the different ways which could be thought of – upside down, wrong end first, inside out,
fore-and-aft, and thortships – and then know what to do on gray nights when it hadn't any shape
at all.’
Twain developed a deep admiration for his fellow navigators, saying of a pilot that his ‘movements
were entirely free; he consulted no one, he received commands from nobody, he promptly
resented even the merest suggestions. Indeed, the law of the United States forbade him to listen to
commands or suggestions’. The main reason for this high status was the ‘faculty which a pilot must
incessantly cultivate until he has brought it to absolute perfection. Nothing short of perfection will
do. That faculty is memory.’
Twain describes the pilots’ ability to be guided by their memory in the face of all distraction, as well
as the highly focused nature of their superior retentive faculty, so that they might read the river
exactly – but not recall what they’d had for breakfast. He also mentions one pilot whose prodigious
memory was global in its capacity, but with the disadvantage that he could not forget anything, so
he was constantly distracted. He might start telling a funny story about a dog but then veer off into
references to owners, their families, the prices of fodder and livestock, circuses, Africa, religion and
the power of prayer; mentioning nothing more about the dog.
In time, the pilots established a closed shop, the Pilots’ Benevolent Association, which added an
important supplement to the powers of their memories. This involved a system of locked boxes that
were kept at all main stopping points on the river and which could only be opened with special keys
held by Association pilots, providing a means whereby information could be securely shared. This
improved safety on the river so much that the pilots’ monopoly was enforced by ‘a power behind
the throne that was greater than the throne itself. It was the underwriters!’
Thus, the best results came from cooperation added to the power of individual memory. Where
does the best balance lie today between using our trained memories and outsourcing the task to
search engines and mobile devices?
The British Journal of Psychiatry (2018)
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